Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril

Reneland, R; Alvarez, E; Andersson, P-E; Haenni, A; Byberg, L; Lithell, H
March 2000
Journal of Human Hypertension;Mar2000, Vol. 14 Issue 3, p175
Academic Journal
The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension. Twenty-six patients were treated with 50-100 mg atenolol and 27 patients with 2-4 mg trandolapril o.d. Intravenous glucose tolerance tests, euglycaemic hyperinsulinaemic clamps and serum lipid measurements were performed after 8 and 48 weeks of active treatment. After 48 weeks insulin sensitivity was reduced by 23% by atenolol while it remained unchanged during trandolapril treatment (+0.5%, P = 0.0010 for difference between treatments, ANCOVA). The effect on triglycerides (+22% vs 28.5%) and high-density lipoprotein cholesterol (-13% vs +0.7%) also differed significantly between atenolol and trandolapril. Results after 8 weeks were similar. Glucose tolerance was not affected by either drug. Atenolol reduced diastolic blood pressure (DBP) better than tran-dolapril (-15.3 mm Hg vs -6.6 mm Hg for supine DBP after 48 weeks, P = 0.012). The difference in effect on insulin sensitivity between the drugs corresponded to 25% of the baseline values of insulin sensitivity, and persisted over 48 weeks of treatment. The choice of anti-hypertensive treatment could influence the risk of diabetes associated with treated hypertension.


Related Articles

  • A PROSPECTIVE STUDY OF INSULIN RESISTANCE IN GAUCHER DISEASE TYPE 1 PATIENTS WITH NORMAL WEIGHT, UNDER ENZYME REPLACEMENT THERAPY. Zimmermann, A.; Grigorescu-Sido, P.; Rossmann, H.; Lackner, K. J.; Drugan, C.; Khzouz, C. Al; Bucerzan, S.; Nascu, I.; Popp, R. A.; Zimmermann, T.; Weber, M. M. // Acta Endocrinologica (1841-0987);2015, Vol. 11 Issue 2, p180 

    Context. A certain degree of insulin resistance in patients with Gaucher disease type 1 (GD) under enzyme replacement therapy (ERT) was reported. Data on insulin sensitivity in treatment naïve patients are inconsistent. Objective. To analyse prospectively changes in parameters of insulin...

  • Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle. Niimi, M.; Ogawara, T.; Yamashita, T.; Yamamoto, Y.; Ueyama, A.; Kambe, T.; Okamoto, T.; Ban, T.; Tamanoi, H.; Ozaki, K.; Fujiwara, T.; Fukui, H.; Takahashi, E.; Kyushiki, H.; Tanigami, A. // Journal of Human Genetics;2001, Vol. 46 Issue 10, p566 

    Glutamine:fructose-6-phosphate amidotransferase (GFAT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway, which plays an important role in hyperglycemia-induced insulin resistance. To evaluate the role of GFAT1 expression, we analyzed the expression profiles of GFAT1 mRNA in...

  • High-Density Haplotype Structure and Association Testing of the Insulin-Degrading Enzyme (IDE) Gene With Type 2 Diabetes in 4,206 People. Florez, Jose C.; Wiltshire, Steven; Agapakis, Christina M.; Burtt, Noël P.; de Bakker, Paul I. W.; Almgren, Peter; Boström, Kristina Bengtsson; Tuomi, Tiinamaija; Gaudet, Daniel; Daly, Mark J.; Hirschhorn, Joel N.; McCarthy, Mark I.; Altshuler, David; Groop, Leif // Diabetes;Jan2006, Vol. 55 Issue 1, p128 

    The insulin-degrading enzyme is responsible for the intracellular proteolysis of insulin. Its gene IDE is located on chromosome 10, in an area with suggestive linkage to type 2 diabetes and related phenotypes. Due to the impact of genetic variants of this gene in rodents and the function of its...

  • Insulin augments matrix metalloproteinase-9 expression in monocytes Fischoeder, Arne; Meyborg, Heike; Stibenz, Dietger; Fleck, Eckart; Graf, Kristof; Stawowy, Philipp // Cardiovascular Research;Mar2007, Vol. 73 Issue 4, p841 

    Abstract: Objective: Insulin resistance and hyperinsulinemia are major causes of cardiovascular morbidity and mortality. Matrix metalloproteinases (MMPs), highly expressed in activated mononuclear cells in vulnerable atherosclerotic lesions, are the main proteolytic enzymes controlling plaque...

  • Insilico Evaluation of Inhibitory Profiles of Phytochemicals for ACC Domains. Rajasekaran, A.; Santhosh, S.; Arulkumaran, K. S. G.; Periyasamy, M. // Asian Journal of Research in Chemistry;Feb2011, Vol. 4 Issue 2, p308 

    Evaluating acetyl-CoA carboxylase (ACC) as the target enzyme for the treatment of hyperlipidemia can lead to the detection of new inhibitors that can potentially be optimized as lipid lowering agents and could also form a novel method of screening a large number of plant constituents. Inhibition...

  • The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway. Yao, Hong; Han, Xiangyang; Han, Xiuzhen // American Journal of Cardiovascular Drugs;Dec2014, Vol. 14 Issue 6, p433 

    Apoptosis occurs frequently in myocardial infarction, oxidative stress injury, and ischemia/reperfusion injury, and plays a pivotal role in the development of heart diseases. Inhibition of apoptosis alone does not necessarily lead to meaningful rescue in terms of either cardiomyocyte survival or...

  • Overexpression of the Sirtuin Sirt1 Increases Insulin Sensitivity in Aging Mice. Banks, Alexander; Kon, Ning; Knight, Collette; Rossetti, Luciano; Accili, Domenico; Gu, Wei // Diabetes;Jun2007 Supplement 1, Vol. 56, pA61 

    Sirtuins are enzymes with protein deacetylase or GDP-ribosylase activity. Gain-of-function of Sir2 alpha, the prototypical Sirtuin, increases lifespan in yeast and nematodes. Mammalian SirT1, the closest ortholog of Sir2 alpha, has been shown to possess deacetylase activity. Among its substrates...

  • White Blood Cells Mediate Insulin Resistance.  // Today's Dietitian;Oct2012, Vol. 14 Issue 10, p80 

    The article reports that researchers have found that neutrophils, an abundant type of white blood cell play a role in mediating insulin resistance. The researchers discovered that an enzyme secreted by neutrophils called neutrophil elastase impairs insulin signaling and boosts resistance. It is...

  • HIV Protease Inhibitors Inhibit Insulin-Degrading Enzyme (IDE) Function. Hamel, Frederick; Siford, Gerri; Bennett, Robert; Fawcett, Janet; Duckworth, William; Swindells, Susan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA665 

    Long term use of HIV protease inhibitors (PI) may result in dyslipidemia, insulin resistance, or diabetes. A possible target of these inhibitors is insulin-degrading enzyme ODE), winch plays a critical role in insulin action. We have shown that IDE will form a complex with the proteasome, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics